This Article Full Text (OnlineFirst PDF) All Versions of this Article: 0269881108089580v1 23/2/168    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ray, R Articles by Lerman, C Search for Related Content PubMed PubMed Citation Articles by Ray, R Articles by Lerman, C Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Quitting Smoking Social Bookmarking                         What's this?

Effects of atomoxetine on subjective and neurocognitive symptoms of nicotine abstinence

¹ Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA
² Department of Psychiatry, Transdisciplinary Tobacco Use Research Center, University of Pennsylvania, Philadelphia, PA, USA
³ Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA

^* To whom correspondence should be addressed.

	Abstract

Abstract

Nicotine dependence has been linked to attention-deficit hyperactivity disorder (ADHD) symptoms in both clinical and general populations. This behavioural pharmacology study used a within-subject, double-blind, crossover design to test the effects of atomoxetine, a medication for ADHD, on nicotine abstinence symptoms. Fifty non treatment–seeking smokers (15 cigarettes/day) completed a baseline session when they were smoking as usual and then two laboratory testing sessions after overnight abstinence and treatment with 7 days of either atomoxetine (1.2 mg/kg) or placebo. During each laboratory session, participants completed subjective measures of abstinence symptoms and performed neurocognitive tasks. In mixed effects models, atomoxetine, compared with placebo, was found to be associated with a reduction in abstinence-induced subjective withdrawal symptoms. Atomoxetine was also associated with significant reductions in self-reported smoking urges amongst smokers who scored high on a baseline measure of smoking for stimulation. However, atomoxetine had no effect on any of the cognitive tasks employed in the study. Thus, atomoxetine may reduce cravings to smoke among smokers who use nicotine to increase arousal.

Key Words: atomoxetine, nicotine, neurocognitive, attention, withdrawal

First published on May 30, 2008, doi:10.1177/0269881108089580

Journal of Psychopharmacology 2009;23:168.

A more recent version of this article appeared on March 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. B. Baker, K. M. Cummings, D. K. Hatsukami, C. A. Johnson, C. Lerman, R. Niaura, and S. S. O'Malley Transdisciplinary Tobacco Use Research Centers: Research achievements and future implications Nicotine Tob Res, October 1, 2009; 11(10): 1231 - 1244. [Full Text] [PDF]